Laura is a Principal on the investment team at RA Capital Management. Laura works on both public and private investments and serves as a board director for Artiva Biotherapeutics and Acumen Pharmaceuticals and as a board observer for Vor Biopharma. Previously, Laura covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders. Laura holds a BA in biology and psychology from Harvard University, and a PhD in neuroscience from MIT. Her graduate research investigated synaptic translation in syndromic autism.